Pathologic complete response (pCR) after neoadjuvant therapy of breast cancer is a surrogate end point of individual long-term benefit,
1,2 and allows for rapid testing of new therapies, and discovery or validation of predictive or prognostic biomarkers.
3 The growing number of candidate new drugs and the established awareness that breast cancer is a group of different diseases with different molecular characteristics and different sensitivity to therapies has led to a greater interest in evaluating these agents in a neoadjuvant setting. The latter approach is an easily applicable clinical tool to rapidly rank the antitumor activity of new therapies in subgroups of patients selected for homogeneous molecular characteristics of the tumor.
4